Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Allegretti M, et al. Among authors: gasparro s. Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z. Mol Cancer. 2021. PMID: 34839818 Free PMC article. No abstract available.
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F. Fabi A, et al. Among authors: gasparro s. Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28. Future Oncol. 2017. PMID: 29182361
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL, Bria E, Montemurro F, Cognetti F, Fabi A. Rossi V, et al. Among authors: gasparro s. Cancers (Basel). 2019 Oct 26;11(11):1661. doi: 10.3390/cancers11111661. Cancers (Basel). 2019. PMID: 31717791 Free PMC article.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Among authors: gasparro s. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Vincenzi B, et al. Among authors: gasparro s. Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. Cancer. 2009. PMID: 19626652 Free article. Clinical Trial.
18 results